Open Access

Intestinal malrotation as a misdiagnosis of pediatric colchicine resistant familial Mediterranean fever

Pediatric Rheumatology201513:45

https://doi.org/10.1186/s12969-015-0044-6

Received: 14 October 2015

Accepted: 4 November 2015

Published: 10 November 2015

Abstract

Background

Familial Mediterranean fever (FMF) is a disorder characterized by recurrent attacks of fever and serosal inflammation, particularly abdominal pain. Other disease processes, including medical and surgical emergencies, may mimic FMF, especially in atypical cases.

Case Presentation

We present a case of an adolescent male, referred to us with a diagnosis of colchicine resistant FMF, ultimately diagnosed with intestinal malrotation and recurrent volvulus.

Conclusions

In atypical presentations of FMF with potential “red flags”, a thorough patient history is extremely important and should result in prompt referral for the appropriate diagnostic tests.

Keywords

Familial Mediterranean fever Intestinal malrotation Volvulus Colchicine resistance

Background

Familial Mediterranean Fever (FMF), the most common monogenic autoinflammatory syndrome, is characterized by recurrent episodes of fever and serosal inflammation, including abdominal pain and vomiting. Intestinal malrotation which occurs as a result of an arrest of normal rotation of the embryonic gut, has a varied clinical presentation from infancy through adolescence and adulthood [1, 2]. We present a case of an adolescent male, referred to us with recurrent vomiting and abdominal pain, initially diagnosed with FMF that was resistant to colchicine, ultimately diagnosed with intestinal malrotation.

Case presentation

A 14 year old male of mixed Sephardic-Ashkenazi Jewish ancestry was referred to our Pediatric Rheumatology Clinic with “colchicine resistant FMF”. From early infancy he suffered from recurrent afebrile episodes of yellowish-greenish vomiting with abdominal pain. Episodes occurred every 1 to 2 weeks, lasting for 1–3 days. Exercise, stress and infections were precipitants of episodes. The patient did not develop rashes, joint/muscle or chest pain. He was hospitalized during several episodes due to dehydration, easily corrected by intravenous fluids. His school attendance was severely impaired, missing about 2 days every week. His father was diagnosed with FMF, after years of recurrent fever, abdominal pain and vomiting, with compound heterozygous mutations on the MEFV gene (M694V/E148Q). Following father’s diagnosis, our patient underwent genetic analysis at age 11 years and a heterozygote E148Q mutation was found. Colchicine was initiated and he received up to 1.5 mg/d for 2 years prior to his referral, with no clinical improvement. He underwent investigations by multiple pediatric gastroenterologists and metabolic diseases specialists, and his laboratory evaluation was normal including: acute phase reactants (even during episodes), blood counts, liver and muscle enzymes, fibrinogen, celiac profile, amino-acids, organic acids, acyl-carnitine and E3 mutation. Abdominal radiographs and ultrasound were normal. His physical examination was unremarkable except for low weight (7th percentile). Due to the history of bilious vomiting since his neonatal period he was referred by us for an upper gastrointestinal series (UGI). This demonstrated malposition of the ligament of Treitz and a corkscrew appearance of the duodenum, consistent with malrotation (Fig. 1). After a successful Ladd procedure with classical findings of malrotation but no intestinal ischemia, the patient is feeling well, with no further vomiting episodes, a rapid catch up in the growth curves and full school attendance.
Fig. 1

Upper gastrointestinal study (UGI) demonstrating intestinal malrotation and volvulus with abnormal position of the duodenal-jejunal junction to the right of the spine. Normally the duodenum should sweep across from right to left across the spine (dashed line shows the left spinal pedicles). A corkscrew appearance of the duodenum (arrow) demonstrates the volvulus

Discussion and conclusion

We present a patient with intestinal malrotation who was initially diagnosed with FMF and treated for 2 years with an adequate dose of colchicine with no response. Fortunately, he did not develop bowel damage after years of recurrent attacks of midgut volvulus.

While the patient fulfilled clinical diagnostic criteria for FMF (Table 1) according to the long-(but not short) version of the Tel-Hashomer criteria [3] (one minor and six supportive criteria), and the Yalcinkaya pediatric criteria [4], several “red-flags” led us to consider an alternative diagnosis.
Table 1

Clinical diagnostic criteria for familial Mediterranean fever (FMF)

Tel-Hashomer Criteria (adapted from reference #3: Livneh A, et al. Arthritis Rheum 1997;40:1879–1885)

Long Version

Major Criteria

 Typical attacks (≥3 of the same type, rectal temp ≥38 °C, attacks lasting 12 h to 3 days)

 1.Peritonitis

 2.Pleuritis (unilateral) or pericarditis

 3.Monoarthritis (hip, knee, ankle)

 4.Fever alone

Minor Criteria

 1. Incomplete attacks (typical attacks including one of the following sites: abdomen, chest or joint with 1 or 2 of the following exceptions: 1) Temperature < 38 °C, 2) attacks lasting 6–12 h or 3–7 days, 3) no signs of peritonitis during abdominal attacks, 4) localized abdominal pain, 5) arthritis in joints other than hip, knee or ankle)

 2. Exertional leg pain

 3. Favorable response to colchicine

Supportive Criteria

 1. Family history of FMF

 2. Appropriate ethnic origin

 3. Age <20 year at disease onset

 4–7 are related to features of attacks:

 4. Severe, requiring bed rest

 5. Spontaneous remission

 6. Symptom-free interval

 7. Transient inflammatory response with one or more abnormal test result(s) for white blood cell count, erythrocyte sedimentation rate, serum amyloid A, and /or fibrinogen

 8. Episodic proteinuria/hematuria

 9. Unproductive laparotomy or removal of “white” appendix

 10. Consanguinity of parents

 An FMF diagnosis requires ≥1 major criteria, or ≥2 minor criteria, or 1 minor criteria plus ≥5 supportive criteria, or 1 minor criteria plus ≥4 of the first 5 supportive criteria.

Short Version

Major criteria

 1.Recurrent febrile attacks accompanied by peritonitis, synovitis or pleuritis.

 2.Amyloidosis of the AA-type without predisposing disease.

 3.Favorable response to continuous colchicine treatment.

Minor criteria

 4. Recurrent febrile attacks

 5. Erysipelas-like erythema

 6. FMF in a first degree relative

Definitive diagnosis: 2 major or 1 major and 2 minor.

Probable diagnosis: 1 major and 1 minor

Yalçinkaya Pediatric Criteria (adapted from reference #4: Yalçinkaya F, et al. Rheumatology (Oxford, England) 2009;48:395–8)

Criteria

Description

Fever

Axillary temperature of >38 °C, 6–72 h of duration, ≥3 attacks

Abdominal pain

6–72 h of duration, ≥3 attacks

Chest pain

6–72 h of duration, ≥3 attacks

Arthritis

6–72 h of duration, ≥3 attacks, oligoarthritis

Family history of FMF

 

Two of five criteria diagnose FMF

  1. 1.

    Neonatal onset of FMF is uncommon [57]. About 31 % percent of patients with FMF present by age 2 years (mean 1.1 years) [8], 80 % by 10 years and 90 % by 20 years, but only about 5 % by 2 months of age. The most common presentation in the infants is just “fussiness”. In almost all others fever is part of the presentation [7, 8], thus isolated vomiting in patients under 1 year of age is very uncommon.

     
  2. 2.

    Bilious vomiting is not characteristic in FMF.

     
  3. 3.

    The lack of fever and other symptoms characteristic of FMF. These would be expected in a patient with severe FMF based on the frequency of attacks, age of onset and lack of response to colchicine [6, 9].

     
  4. 4.

    Normal acute phase reactants during attacks.

     
Besides clinical criteria, the diagnosis of our patient and treatment with colchicine was initially supported by finding a heterozygous E148Q mutation on the MEFV gene. Genetic testing in FMF is only considered supportive and not diagnostic, particularly in atypical cases. When two mutations are found, FMF diagnosis is confirmed. In atypical cases where only one mutation is found a trial of colchicine is often offered. Indeed up to 30 % of FMF have only a heterozygote exon ten mutation [10]. However, controversy exists regarding the role of some MEFV variations (Table 2), particularly for the exon 2 E148Q glutamic acid to glutamine substitution [11]. Initially, this sequence variation was described as a disease causing mutation with low penetrance and mild symptoms. However, recent studies showed a similar frequency of E148Q among FMF patients and controls, and those findings support the hypothesis that E148Q is a benign polymorphism and not a disease causing mutation [1214]. E148Q may be a disease modifier in other rheumatologic conditions [1517]. E148Q may also modify the severity of FMF when found on the same allele with other mutations. FMF patients who are homozygous for the complex allele (E148Q-V726A/E148Q-V726A), or compound heterozygotes (E148Q-V726A/V726A), have a more severe disease compared to patients homozygous for V726A [14]. In our patient the E148Q substitution is likely to be only a polymorphism, unlike his father who had a compound heterozygote M694V/E148Q mutation.
Table 2

Clinical significance of the common mutations/variations found in the MEFV gene

Mutations associated with classic familial Mediterranean fever (FMF)

 M694V

 M694I

 M680I

 V726A

Mutations associated both with classic and atypical FMF

 A744S

 K695R

 R761H

Mutations usually associated with atypical FMF

 P369S/R408Q (often in cis)

 R329H

Varients considered polymorphisms

aE148Q

aR202Q

aCan be associated with disease in compound heterozygote with other mutations

Multiple other disease processes may closely resemble FMF and must be excluded in atypical cases, such as surgical emergencies, metabolic diseases and other periodic fever syndromes (Table 3) [18, 19]. Both FMF diagnostic criteria have excellent but not 100 % specificity for the population in whom it was developed (99 % for adults with the Tel-Hashomer criteria [3], 92 % for children with the Yalcinkaya criteria [4]). However, the Tel-Hashomer criteria developed for adults had a lower specificity (54 %) in children [4]. Therefore, in atypical cases with potential “red flags” a thorough patient history is extremely important and should result in prompt referral for the appropriate diagnostic tests.
Table 3

Differential diagnosis of recurrent vomiting (often with abdominal pain) other than familial Mediterranean fever (FMF) in the pediatric population, by age

Neonate/infancy

Childhood

Adolescence

GERD

GERD

GERD

Anatomic obstruction a

>Anatomic Obstruction a

IBD

Dietary protein intolerance

PUD

PUD

Metabolic disorderb

Pancreatitis

Cyclic vomiting

Renal disorder/obstruction

Cyclic vomiting

Pancreatitis

Adrenal crisis

Metabolic disordersb

Biliary colic

  

Renal colic

  

Acute intermittent porphyriab

  

Anatomic Obstructiona

aIncludes malrotation with midgut volvulus, pyloric stenosis, intussusception, Hirschsprung disease, congenital atresia/stenosis/webs, incarcerated hernia

bIncludes urea cycle defects, organic acidemias, fatty acid oxidation defects, disorders of gluconeogenesis in infancy, and porphyria in childhood/adolescence

GERD gastroesophageal reflux, IBD inflammatory bowel disease, PUD peptic ulcer disease

The common causes in each age are marked in bold. Functional gastrointestinal disorders are a common cause of recurrent abdominal pain but without vomiting

Malrotation is an incomplete rotation of the intestine during fetal development. The mesentery, including the superior mesenteric artery, is tethered by a narrow stalk, which can twist around itself, and produce life threatening midgut volvulus, with an acute presentation of small bowel obstruction. Traditionally, intestinal malrotation is considered primarily a disease of infancy with infrequent occurrence beyond the first year of life. However, recent studies demonstrate that the prevalence of malrotation in older children and adults appears to be higher than previously thought [1, 2]. Upper gastrointestinal series is the gold standard imaging test for diagnosis. Surgical intervention is recommended regardless of age, and presentation of volvulus requires an emergency procedure.

In summary, alterative diagnoses to FMF should be considered in cases of atypical attacks as in our patient, even if fulfilling diagnostic criteria and supported partially by a heterozygous mutation in the MEFV gene. In some cases, as we described, the correct diagnosis may represent a surgical or medical emergency requiring prompt treatment.

Consent

Written informed consent was obtained from the patient’s parents for publication of this Case Report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Declarations

Acknowledgments

We would like to thank Dr. Ruthi Cytter who helped in preparing the figure.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Pediatric Department, Shaare Zedek Medical Center
(2)
Pediatric Rheumatology Unit, Shaare Zedek Medical Center

References

  1. Nagdeve NG, Qureshi AM, Bhingare PD, Shinde SK. Malrotation beyond infancy. J Pediatr Surg. 2012;47:2026–32.View ArticlePubMedGoogle Scholar
  2. Aboagye J, Goldstein SD, Salazar JH, Papandria D, Okoye MT, Al-Omar K, et al. Age at presentation of common pediatric surgical conditions: reexamining dogma. J Pediatr Surg. 2014;49:995–9.View ArticlePubMedGoogle Scholar
  3. Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum. 1997;40:1879–85.View ArticlePubMedGoogle Scholar
  4. Yalçinkaya F, Ozen S, Ozçakar ZB, Aktay N, Cakar N, Düzova A, et al. A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford). 2009;48:395–8.View ArticleGoogle Scholar
  5. Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med. 1967;43:227–53.View ArticlePubMedGoogle Scholar
  6. Ben-Chetrit E, Levy M. Familial Mediterranean fever. Lancet. 1998;351:659–64.View ArticlePubMedGoogle Scholar
  7. Ozcakar ZB, Sabin-Kunt S, Ozdel S YF. Neonatal onset familial Mediterranean fever. Pediatr Rheumatol 2015;13 (suppl 1):79.Google Scholar
  8. Padeh S, Livneh A, Pras E, Shinar Y, Lidar M, Feld O, et al. Familial Mediterranean fever in the first 2 years of life: a unique phenotype of disease in evolution. J Pediatr. 2010;156:985–9.View ArticlePubMedGoogle Scholar
  9. Mor A, Shinar Y, Zaks N, Langevitz P, Chetrit A, Shtrasburg S, et al. Evaluation of disease severity in familial Mediterranean fever. Semin Arthritis Rheum. 2005;35:57–64.View ArticlePubMedGoogle Scholar
  10. Marek-Yagel D, Berkun Y, Padeh S, Abu A, Reznik-Wolf H, Livneh A, et al. Clinical disease among patients heterozygous for familial Mediterranean fever. Arthritis Rheum. 2009;60:1862–6.View ArticlePubMedGoogle Scholar
  11. Naimushin A, Lidar M, Ben Zvi I, Livneh A. The structural effect of the E148Q MEFV mutation on the pyrin protein: a study using a quantum chemistry model. Isr Med Assoc J. 2011;13:199–201.PubMedGoogle Scholar
  12. Ben-Chetrit E, Lerer I, Malamud E, Domingo C, Abeliovich D. The E148Q mutation in the MEFV gene: is it a disease-causing mutation or a sequence variant? Hum Mutat. 2000;15:385–6.View ArticlePubMedGoogle Scholar
  13. Tchernitchko D, Legendre M, Cazeneuve C, Delahaye A, Niel F, Amselem S. The E148Q MEFV allele is not implicated in the development of familial Mediterranean fever. Hum Mutat. 2003;22:339–40.View ArticlePubMedGoogle Scholar
  14. Marek-Yagel D, Bar-Joseph I, Pras E, Berkun Y. Is E148Q a benign polymorphism or a disease-causing mutation? J Rheumatol. 2009;36:2372.View ArticlePubMedGoogle Scholar
  15. Rabinovich E, Livneh A, Langevitz P, Brezniak N, Shinar E, Pras M, et al. Severe disease in patients with rheumatoid arthritis carrying a mutation in the Mediterranean fever gene. Ann Rheum Dis. 2005;64:1009–14.PubMed CentralView ArticlePubMedGoogle Scholar
  16. Rabinovich E, Shinar Y, Leiba M, Ehrenfeld M, Langevitz P, Livneh A. Common FMF alleles may predispose to development of Behcet’s disease with increased risk for venous thrombosis. Scand J Rheumatol. 2007;36:48–52.View ArticlePubMedGoogle Scholar
  17. Shinar Y, Kosach E, Langevitz P, Zandman-Goddard G, Pauzner R, Rabinovich E, et al. Familial Mediterranean FeVer gene (MEFV) mutations as a modifier of systemic lupus erythematosus. Lupus. 2012;21:993–8.View ArticlePubMedGoogle Scholar
  18. Sreedharan R, Liacouras CA, Geme 3 JWS BR. Major symptoms and signs of digestive tract disorders. In: Kliegman RM, Stanton BF, Schor NF, editors. Nelson textbook of pediatrics. 19th edition. Philadelphia: Elsevier; 2011. p. 1240–9. e1.View ArticleGoogle Scholar
  19. Korson M. Metabolic etiologies of cyclic or recurrent vomiting. J Pediatr Gastroenterol Nutr. 1995;21 Suppl 1:S15–9.View ArticlePubMedGoogle Scholar

Copyright

© Heshin-Bekenstein and Hashkes. 2015

Advertisement